A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Recruiting

Phase 1

UB-VV111 with RapamycinA Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Sponsor:

Umoja Biopharma

Code:

NCT06528301

Conditions

Lymphoma, B-Cell

Lymphoma, Non-Hodgkin (NHL)

Lymphoma, Large B-Cell, Diffuse (DLBCL)

Chronic Lymphocytic Leukemia (CLL)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

UB-VV111

rapamycin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-26. This information was provided to ClinicalTrials.gov by Umoja Biopharma on 2025-07-15.